TOV-3041G cell line

Please Enter Your Email ID
Email ID

Cat. #161780

TOV-3041G cell line

Cat. #: 161780

Organism: Human

Tissue: Derived from high-grade serous tumors


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941

Tool Details

Tool Details


  • Name: TOV-3041G cell line
  • Alternate name: TOV-3041G
  • Cancer: Gynaecologic cancer
  • Research fields: Cancer
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from high-grade serous tumors
  • Donor: Age of diagnosis: 61; BRCA hereditary status: negative Grade 3 – Stage IVA; Mutations: P53 negative; Carboplatin/Taxol
  • Morphology: Small epithelial type cells and consistently formed compact spheroids
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serious tumors of patient who was treated with chemotherapy before collection due to recurring disease. Cell line was derived from rare case of HGS EOC where a somatic TP53 mutation was not detected by mutation screening. However, the absense of p53 mRNA and protein in addition to impaired p53 function was detected in this line. Therefore, this cell line has features characteristic of a p53-null mutation. It is suggested that in this cell line, TP53 regulation occurs at the mRNA level rather than protein level.
  • Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
  • Additional notes: Patient 3041 was age 61 at diagnosis, BRCA hereditary status was negative, and disease stage was IVA. First line treatment was carboplatin/taxol, then sugery, followed by Cisplatin/taxol. Patient had no prior personal history of cancer but was part of a breast cancer prevention trial of tamoxifen previously. Year of sampling was 2007.


  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin


  • Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
  • 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
  • 15(9):2566. PMID: 37174032